Figure 3
Molecular mechanism of GZ17-6.02 in vitro. (A) Volcano plot of DEGs between control and GZ17-6.02 treated HH cells. (B) Volcano plot of DEGs between control and GZ17-6.02 treated MyLa cells. (C) GSEA results showing Hallmark pathways upregulated and downregulated in HH cells following GZ17-6.02 treatment. (D) GSEA results showing Hallmark pathways upregulated and downregulated in MyLa cells following GZ17-6.02 treatment. (E) Top downregulated pathways in GZ17-6.02 treated HH cells from Hallmark EnrichR enrichment analysis of phosphor-proteomic data. (F) Top downregulated pathways in GZ17-6.02 treated MyLa cells from Hallmark EnrichR enrichment analysis of phosphor-proteomic data. FC, fold change; sig, significant; TNF, tumor necrosis factor; UV, ultraviolet; IFN, interferon; NES, normalized enrichment score.
